ViewRay has secured approval from the China Food and Drug Administration (CFDA) for its MRIdian System, a medical instrument developed for the treatment of cancers.
The clinical MRI-guided radiation therapy system incorporates full-time MR imaging, cobalt radiation delivery and intelligent software automation to treat cancers across the body.
MRIdian system enables clinicians to locate, target and track the position and shape of soft-tissue tumors during radiation.
Through using MRIdian system, the clinicians can visualize and adjust the dose on live anatomy.
According to the company, the MRIdianb system provides the treatment without exposing the patient to the additional ionizing radiation
ViewRay president and CEO Chris Raanes said: “China is one of the largest markets for medical devices in the world, so securing CFDA approval is an important step in our growth strategy.
“Given its population and rising cancer incidence, we believe MRI-guided radiation therapy will be an important cancer fighting tool for doctors and their patients throughout China.”
ViewRay said that it is represented in China by Cowealth Medical Holding.
Cowealth president and CEO Duane Lee said: “We believe MRI-guided radiation therapy is an essential advancement in radiation oncology and look forward to helping expand access to this vital treatment option.”
In August, the company also received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the MRIdian system in the country.